亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Targeting PI3K decreases trogocytosis-mediated CAR T cell fratricide

嵌合抗原受体 CD19 癌症研究 抗原 细胞生物学 T细胞 免疫系统 PI3K/AKT/mTOR通路 生物 单克隆抗体 化学 细胞 B细胞 分子生物学 肿瘤微环境 抗原提呈细胞 肿瘤抗原 表位 CD28 免疫学 抗体
作者
Tarang Sharma,Maday Galeana Figueroa,Kishan Kumar Nyati,Ravi K. Shah,Meera Mohan,Parameswaran Hari,Tim Luetkens,Sabarinath Venniyil Radhakrishnan
出处
期刊:Leukemia [Springer Nature]
标识
DOI:10.1038/s41375-026-03129-4
摘要

CAR T cell-mediated trogocytosis (CMT) is a proposed mechanism of tumor immune evasion, in which the cognate interaction between CAR T cells and tumor cells results in the transfer of target antigen from the tumor cell surface to the CAR T cell. In addition to the emergence of antigen-negative target cells, antigen-positive CAR T cells become the targets of other CAR T cells in a process called fratricide (Fig. 1a ). Multiple strategies to overcome CMT have been pursued by different research groups. Hamieh et al. [ 1 ], who initially described CMT, used a strategy that simultaneously targets multiple antigens to reduce the risk of tumor escape. Lu et al. demonstrated that overexpressing 25-hydroxycholesterol (25HC) in mesothelin-targeting CAR T cells decreased trogocytosis and improved CAR T cell efficacy. They also discovered that activating transcription factor-3 (ATF3) downregulated cholesterol 25-hydroxylase expression, thereby reducing 25HC expression and increasing CMT. Li et al. [ 2 ] employed a dual CAR system, one that binds CD19 on tumor cells and activates the NK cells, and an inhibitory CAR targeting CS1 to prevent fratricide. Olson et al. [ 3 ] demonstrated that using the low-affinity CD19 scFv, CAT, instead of FMC63 in CAR T cells decreased CMT. Koh et al. [ 4 ] simultaneously administered anti-CD19 monoclonal antibody along with CD19 CAR T/NK cells and showed that the combination treatment reduced trogocytosis resulting in better tumor control and survival in vivo. However, the mechanism driving CMT remains poorly understood. Fig. 1: PI3K interaction with CD3ζ regulates CAR trogocytosis. Full size image a Schema representing CAR T cell trogocytosis, CAR-antigen (Ag) interaction leads to loss of Ag from tumor cells and Ag presentation on CAR T cells leads to fratricide. b Schema representing components of wild type (WT) CAR and mutant form that lacks signaling domain CD3ζ and 4-IBB (ΔSig CAR T cells). Components of the wild-type CAR include an antigen-binding domain, a single-chain variable fragment (scFv), a hemagglutinin tag (HA), a CD8 transmembrane domain (TMD), a co-stimulatory domain 4-1BB, and a signaling domain CD3ζ. c–e WT or ΔSig CD19 CAR T cells were co-cultured with B-ALL cell line NALM6 at a 1:1 ratio for one hour, and surface expression of CD19 was measured by flow cytometry. c Panel showing a representative histogram of CD19 expression on NALM6 cells. CD19 fluorescence intensity represented as median on NALM6 cells d and CAR T cells e of four replicates and statistical significance assessed by two-sided Student’s t test. f PI3K p110δ was knocked down using short hairpin RNA (shRNA) in T cell line Jurkat cells stably expressing CD19 CAR. Immunoblotting of cell lysate with antibodies specific for PI3K p110δ and beta actin. g PI3K p110δ knocked down Jurkat CD19 CAR T cells were co-cultured with NALM6 cells at a 1:1 effector: target ratio, and surface expression of CD19 on NALM6 was measured by flow cytometry and represented as a histogram. h Equal numbers of CD19 CAR T cells were incubated with different concentrations of ME401 in DMSO and cultured for 20 h; live cells were counted by flow cytometry using DAPI as a live-dead marker. Data represented as mean ± SD of triplicates, and statistical significance assessed by one-way ANOVA with Sidak’s multiple comparison test. i CD19 CAR T cells were incubated with specific PI3K p110δ inhibitor ME401at different concentrations for 20 h and then co-cultured with NALM6 cells for one hour at a 1:1 ratio, and the levels of phosphorylated and pan AKT were measured by immunoblotting. j–l CD19 CAR T cells were incubated with ME401 for 20 h and then co-cultured with NALM6 cells for 15 min at a 5:1 E:T ratio j, k or 1:1 ratio for 30 min l , and CD19 expression on NALM6 and CAR T cells was measured by flow cytometry. Data shown in triplicate and statistical significance by an unpaired two-tailed Student’s t-test. m, n ME401 or DMSO-treated CD19 CAR T cells were co-cultured with NALM6 cells for 1 h at a 1:2 E:T ratio, and then fixed, permeabilized, and stained with Phalloidin AF-594, and fluorescence was measured by flow cytometry. o WT or ΔSig CD19 CAR T cells were co-cultured with NALM6 cells at a 1:2 E:T ratio for one hour, and then CAR was pulled down using anti-HA antibodies from cell lysates and probed for the presence of P13K p110δ and CAR protein by western blotting. p BCMA CAR T cells were co-cultured with or without myeloma cell line U266, and CAR was pulled down using anti-HA antibodies and probed for the presence of P13K p110δ and CAR protein by western blotting. q ME401 or DMSO-treated CD19 CAR T cells were co-cultured with NALM6 cells at a 1:2 E:T ratio for one hour, and the CAR protein was pulled down using anti-HA antibody and probed for P13K p110δ and CAR protein by western blotting. r Schema representing the proposed function of PI3K in regulating CAR T cell trogocytosis. All experiments were repeated at least 3 times except for Figs. 1 h , 1 i , and 1 p which were repeated twice. Here, we aimed to elucidate the proximal molecular mechanism driving CMT. We generated CD19 CAR T cells that lack intracellular CD3ζ and co-stimulatory signaling domains (Δsig) (Fig. 1b ) and co-cultured them or wildtype (WT) CD19 CAR T cells with the CD19 + B cell acute lymphoblastic leukemia (B-ALL) cell line, NALM6. We observed significantly greater CD19 loss in NALM6 cells co-cultured with WT compared to Δsig CAR T cells (Fig. 1c, d ). In addition, we found increased transfer of CD19 to WT CAR T cells compared to Δsig CAR T cells (Fig. 1e ). Previous studies on T cell receptor (TCR) trogocytosis identified phosphoinositide-3-kinase (PI3K) as an important mediator of trogocytosis [ 5 ]. CARs and TCRs share CD3ζ, which is critical for PI3K pathway activation. While the PI3K family comprises many isoforms, PI3K p110δ (PI3Kδ), is considered the main PI3K isoform involved in proximal TCR signaling [ 6 ]. We generated CD19 CAR-expressing Jurkat T cells and then downregulated PI3K/p110δ using shRNA (shPI3Kδ, Fig. 1f ). CD19 expression was significantly reduced on NALM6 cells co-cultured with WT compared to shPI3Kδ CD19 CAR Jurkat cells (Fig. 1g ), suggesting that PI3K is an important contributor to CMT. To inhibit PI3K in primary CAR T cells, we used the clinically validated PI3Kδ-specific inhibitor ME401 (zandelisib) [ 7 ]. We first determined the highest concentration of ME401 that does not affect CAR T cell viability to be 2 µM by incubating CD19 CAR T cells with ME401 for 20 h (Fig. 1h ). At the same concentration, we observed that the phosphorylation of AKT, a downstream target of PI3K, was substantially reduced in ME401-treated CAR T cells compared to DMSO-treated CAR T cells confirming PI3K inhibition (Fig. 1i ). Furthermore, PI3K inhibition by ME401 was transient with AKT phosphorylation returning to baseline 72-h post treatment (Supplementary Fig. 1 ) We next co-cultured ME401- or DMSO-treated primary human CD19 CAR T cells with NALM6 cells and observed that CD19 loss on tumor cells (Fig. 1j, k ) and antigen transfer to CAR T cells (Fig. 1l ) was reduced following ME401 treatment. We hypothesized that PI3K may mediate CMT by increasing actin polymerization, which is known to be critical for trogocytosis [ 1 , 8 ]. Indeed, we found that ME401-treated CD19 CAR T cells co-cultured with NALM6 cells exhibited reduced actin cross-linking (Fig. 1m,n ). PI3K-mediated actin polymerization has previously been shown to mediate TCR internalization following PI3K binding to CD3ζ [ 5 ]. To study whether a similar interaction occurs between PI3Kδ and CAR molecules, we co-cultured ∆sig or WT CD19 CAR T cells with NALM6 cells. Following co-culture, CAR-containing complexes were co-immunoprecipitated using an anti-hemagglutinin tag (HA) antibody (Fig. 1b ) and probed for PI3Kδ/p110δ. We found that PI3Kδ was only complexed with CAR in WT CD19 CAR T cells but not Δsig CAR T cells and required the presence of CD19 + target cells, suggesting a specific interaction between CAR and PI3K upon activation (Fig. 1o ). PI3K is known to interact with CD19 in B cells [ 9 ], and we hypothesized that, instead of PI3K binding to the CAR, pull-down of PI3K could be the result of the CAR binding to CD19, which could itself be associated with PI3K in the target cells. To investigate this possibility, we studied whether using a CAR construct targeting an antigen not associated with PI3K would still result in PI3K pull-down. BCMA is not known to bind to PI3K, and co-immunoprecipitation using lysates from BCMA CAR T cells co-cultured with BCMA + myeloma cell line U266B1 (U266) again resulted in pulldown of PI3K (Fig. 1p ). This finding indicates that the CAR-PI3K interaction is agnostic of the CAR target and not the result of PI3K binding to the antigen. We further found that the interaction between CAR and PI3K could be inhibited by pretreating the CAR T cells with ME401 (Fig. 1q ). To test whether PI3K inhibition would affect CMT in the solid tumor setting, we co-cultured ME401 or DMSO pretreated folate receptor-1(FOLR1)-specific CAR T cells with ovarian cell line OVCAR3 and found reduced FOLR1 antigen transfer in the ME401 treated group (Supplementary Fig. 2 ). We suggest a working model of CMT that involves CAR T cell activation-induced PI3K interaction with the CAR, resulting in actin polymerization and subsequent transfer of target antigen, leading to loss of antigen on the tumor cell surface and presentation of antigen on the CAR T cell surface (Fig. 1r ). We next investigated whether this decrease in antigen transfer could result solely from reduced T cell function, specifically anti-tumor activity and proliferation, rather than from a specific effect on CMT. However, ME401-treated CD19 and BCMA CAR T cells showed increased tumor cell killing (Fig. 2a, b , Supplementary Fig. 5a ) and expansion (Fig. 2c, d ) when co-cultured with target cells. This increased CAR T cell expansion was also associated with reduced apoptosis, possibly due to less fratricide (Fig. 2e , Supplementary Fig. 1 ). ME401-treated CD19 and BCMA CAR T cells also exhibited reduced expression of exhaustion markers LAG3, PD1, TIM3, and TIGIT following co-culture (Fig. 2f , Supplementary Fig. 3 ) and no significant changes in CAR T cell phenotype following short PI3K inhibitor pretreatment (Supplementary Fig. 2 , 5b ). Interestingly, despite the increased cytotoxicity of ME401-treated CD19 and BCMA CAR T cells, we observed lower levels of inflammatory cytokines (Fig. 2g , Supplementary Fig. 4 ). Next, we determined whether pretreatment with ME401 could have beneficial effects on CAR T cell fratricide and T cell function in vivo (Fig. 2h ). ME401-pretreated CD19 CAR T cells demonstrated increased in vivo tumor control (Fig. 2i ) and substantially increased CD19 CAR T cell numbers (Fig. 2j,k , Supplementary Fig. 5c ). In addition, ME401-pretreated CAR T cells showed lower expression of LAG3 and PD1 (Fig. 2l, m ) in line with our in vitro results. Fig. 2: PI3K inhibition reduces CAR T cell fratricide and improves efficacy. Full size image a–d CAR T cells are pretreated with ME401 or DMSO (carrier) for 20 h and washed prior to experiments. ME401 (1μM) or DMSO-treated CD19 or BCMA CAR T cells were co-cultured with NALM6 or U266 cells labeled with cell trace far red (CTFR) for 90 min at different E:T ratios. To measure the killing of CAR T cells, an equal number of CAR T cells corresponding to each E:T ratio was cultured without target cells as a control for the same time. Similarly, NALM6 or U266 cells were cultured in the absence of CAR T cells as a control to measure target cell killing. Cell numbers were measured in a fixed-volume co-culture using a Cytek Aurora flow cytometer. Number of viable NALM6 cells or U266 cells (DAPI-) in co-culture with corresponding CAR T cells, normalized to control wells. a, b Number of viable CD19 or BCMA CAR T cells (DAPI-) in the co-culture was normalized to the corresponding CAR T cell number in the control wells c, d . Data represent mean ± SD and statistical significance assessed by multiple unpaired t tests and corrected for multiple groups using the Holm-Šídák method. e ME401 or DMSO treated CD19 CAR T cells were co-cultured with NALM6 cells at 1:1 E:T ratio for 4 h and surface annexin V measured by flow cytometry. Data represent mean ± SE and statistical analysis using unpaired two-tailed Student’s t-test. f ME401 or DMSO-treated CD19 CAR T cells were co-cultured with NALM6 cells at an E:T ratio of 2.5:1 for 24 h, and surface expression of PD1, LAG3, TIGIT, and TIM3 was measured by flow cytometry and represented as a histogram normalized to the mode. g ME401 or DMSO-treated CD19 CAR T cells were co-cultured with NALM6 at different E:T ratios for 4 h, and cytokine levels in cell culture supernatant were measured using Legend Plex cytokine bead array using flow cytometry. Data shown as mean of triplicates for each condition represented as a heat map. All in vitro experiments were repeated at least three times except Fig. 2 g which was done twice. h . 8–12-week-old female NRG mice were irradiated with 500 cGy and then engrafted with firefly-luciferase expressing NALM6 cells and treated with either ME401 or DMSO-treated CD19 CAR T cells after 14 days. Tumor burden was measured as total flux (photons/sec) of luciferase activity prior to CAR T injection and two days later at the end of the experiment, and fold change was calculated for each mouse. The fold change was normalized to the average fold change of mice that received DMSO-treated CAR T cells. Data represent 6 mice per group as mean ± SD fold change; statistical significance was determined using a two-tailed unpaired t-test. i Flow cytometry was performed on splenocytes isolated from these animals to identify CAR T cells (hCD45 + hCD3) and they were normalized to mouse CD45 for each individual mice and represented as fold change compared to DMSO group j , representative zebra plots of CAR T cells from one mice each from DMSO and ME401 group (gated live+mCD45-hCD45 + hCD3 + ) k , surface expression of LAG3 ( l ) and PD1 ( m ). Data shown of two individual experiments with 6 mice each in each group as mean±SD fold change for i and mean±SD fluorescence intensity l, m , statistical significance determined using two-tailed unpaired Student’s t-test. CMT is increasingly recognized as a potential tumor escape mechanism in the CAR T cell field [ 2 , 10 ]. In this study, we have shown that PI3K plays a key role in regulating CMT and that inhibition of PI3K in CAR T cells using a clinically validated inhibitor substantially reduces CMT. We further show in vitro and in vivo that CAR T cell fratricide is significantly reduced when CAR T cells are pretreated with PI3Kδ inhibitor. We have also demonstrated that these CAR T cells are less exhausted, less apoptotic, and importantly, produce less inflammatory cytokines. Crucially, we show that reduced CMT is associated with increased anti-tumor activity and is not associated with reduced T cell function. We hypothesize that this increase in cytotoxic activity results from the improved persistence and reduced exhaustion of the pretreated CAR T cells. As ME401 is a reversible PI3K inhibitor and our approach of short pretreatment induces only a transient inhibition of PI3K activity it is unlikely to affect long term actin polymerization and CAR T cell function. Previous studies have shown that PI3K inhibition can also alter the fractions of central and effector memory T cells [ 11 , 12 ]. In contrast to these studies, we evaluated here the effect of a short pre-infusion treatment with a PI3K inhibitor on the CAR T cell product, rather than continuous inhibitor treatment in vivo. We did not observe an effect of the short ME401-pretreatment on CAR T cell phenotype and therefore hypothesize that the observed beneficial effects of PI3K inhibition were instead due to immediate effects on CMT and CAR signaling. Our results support a growing body of evidence indicating that PI3K inhibitors may be able to decrease cytokine production without negatively affecting CAR T cell function [ 13 , 14 ]. In short, we demonstrate here a clinically viable intervention, based on the pretreatment of CAR T cell products with a validated PI3Kδ inhibitor, that reduces trogocytosis, fratricide, exhaustion, and cytokine secretion, while increasing CAR T cell persistence and anti-tumor activity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小二郎的应助被令狐大侠采纳,获得10
1秒前
科研通AI6.4的应助被令狐大侠采纳,获得10
1秒前
科研通AI6.2的应助被令狐大侠采纳,获得30
1秒前
田様的应助被令狐大侠采纳,获得10
2秒前
传奇3的应助被令狐大侠采纳,获得10
2秒前
科研通AI65的应助被令狐大侠采纳,获得10
2秒前
orixero的应助被令狐大侠采纳,获得10
2秒前
科研通AI6.3的应助被令狐大侠采纳,获得10
2秒前
科研通AI65的应助被令狐大侠采纳,获得10
3秒前
2589发布了新的文献求助10
5秒前
Chenzr发布了新的文献求助20
13秒前
美满的幼旋完成签到,获得积分10
28秒前
舒心书白完成签到,获得积分10
32秒前
天天挨呲的潜力股完成签到,获得积分10
39秒前
xccccccc发布了新的文献求助10
41秒前
科研通AI6.4的应助被令狐大侠采纳,获得10
52秒前
爆米花的应助被令狐大侠采纳,获得10
52秒前
机智的白卉的应助被令狐大侠采纳,获得10
52秒前
上官若男的应助被令狐大侠采纳,获得10
52秒前
Orange的应助被令狐大侠采纳,获得10
53秒前
丘比特的应助被令狐大侠采纳,获得10
53秒前
syvshc的应助被令狐大侠采纳,获得10
53秒前
wanci的应助被令狐大侠采纳,获得10
53秒前
风吹麦浪的应助被令狐大侠采纳,获得10
53秒前
情怀的应助被令狐大侠采纳,获得30
54秒前
研友_VZG7GZ的应助被炸小鱼采纳,获得10
56秒前
n01W97的应助被科研通管家采纳,获得20
59秒前
6666的应助被科研通管家采纳,获得30
59秒前
1分钟前
zyp完成签到,获得积分20
1分钟前
炸小鱼发布了新的文献求助10
1分钟前
1分钟前
辛勤的涵菡完成签到,获得积分10
1分钟前
1分钟前
Chenzr发布了新的文献求助10
1分钟前
阿双发布了新的文献求助10
1分钟前
领导范儿的应助被xccccccc采纳,获得10
1分钟前
69完成签到,获得积分10
1分钟前
里子完成签到 ,获得积分10
1分钟前
超帅的甜瓜完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185137
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834040
捐赠科研通 7782575
什么是DOI,文献DOI怎么找? 3434520
关于科研通互助平台的介绍 2558743
邀请新用户注册赠送积分活动 2481206